Heart Failure Management

Staging and Initial Assessment

• The American College of Cardiology recommends a staged approach to heart failure management, with treatment tailored to reduce mortality, morbidity, and improve quality of life through guideline-directed medical therapy (GDMT) that includes ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors as the four pillars of treatment 1, 2, 3
• For patients at high risk without structural heart disease or symptoms (Stage A), the American Heart Association suggests focusing on reducing modifiable risk factors (hypertension, hyperlipidemia) and considering ACE inhibitors or ARBs in appropriate patients 1, 3
• For patients with structural heart disease without symptoms (Stage B), the American College of Cardiology recommends ACE inhibitors or ARBs in appropriate patients and beta-blockers in appropriate patients 1, 3
• For patients with structural heart disease with current or prior symptoms (Stage C), the American Heart Association suggests core pharmacological therapy, including ACE inhibitors, beta-blockers, and diuretics for fluid retention 1, 2
• For patients with refractory heart failure requiring specialized interventions (Stage D), the American College of Cardiology recommends considering mechanical circulatory support, heart transplantation, or palliative care 1, 2, 4

Core Pharmacological Therapy

• The American College of Cardiology recommends ACE inhibitors/ARBs/ARNIs as first-line therapy for mortality reduction in patients with heart failure with reduced ejection fraction (HFrEF) 2, 3
• The American Heart Association suggests beta-blockers as essential for reducing mortality and hospitalizations in patients with HFrEF 1, 2
• The American College of Cardiology recommends mineralocorticoid receptor antagonists (MRAs) for patients with recent or current class IV symptoms and monitoring potassium and renal function 2, 5
• The European Society of Cardiology suggests SGLT2 inhibitors as a newer addition to core therapy with proven mortality benefit in both HFrEF and HFpEF 6
• The American College of Cardiology recommends diuretics as essential for symptomatic treatment of fluid overload and titrating dose based on response and symptoms 2, 7

Additional Therapies for Selected Patients

• The American College of Cardiology recommends considering hydralazine and isosorbide dinitrate for patients who cannot tolerate ACE inhibitors/ARBs due to hypotension or renal insufficiency and particularly beneficial in African American patients 2, 5
• The American Heart Association suggests digoxin may be initiated to reduce symptoms and enhance exercise tolerance and monitoring for toxicity, especially in renal impairment 2, 5
• The American College of Cardiology recommends exercise training as adjunctive therapy to improve clinical status in ambulatory patients 5

Management of Acute Decompensation

• The American College of Cardiology recommends promptly administering diuretics to relieve congestion and continuous monitoring of heart rate, rhythm, blood pressure, and oxygen saturation for at least 24 hours in patients hospitalized with acute heart failure 7, 8
• The American Heart Association suggests assessing volume status to guide therapy adjustments and scheduling early follow-up visits within 7-14 days and telephone follow-up within 3 days of discharge 8

Special Considerations for Advanced Heart Failure

• The American College of Cardiology recommends considering mechanical circulatory support, heart transplantation, or palliative care for refractory cases and eligible patients with end-stage disease 2, 4
• The American Heart Association suggests palliative care as effective for improving quality of life in advanced heart failure 2

Interventions Not Recommended

• The American College of Cardiology does not recommend long-term intermittent use of positive inotropic drugs, calcium channel blockers for treatment of heart failure, routine use of nutritional supplements, or hormonal therapies 5

Practical Implementation Tips

• The American College of Cardiology recommends implementing multidisciplinary heart failure disease-management programs for high-risk patients and monitoring renal function and electrolytes regularly, especially after dose changes 2, 8

Heart Failure Management Guideline

Core Pharmacological Management

• The European Heart Journal recommends teaching patients a flexible diuretic regimen based on daily weight monitoring 9
• Multidisciplinary disease management programs, as suggested by the European Heart Journal, improve quality of life, reduce readmissions, and decrease costs by referring high-risk patients to structured HF programs with a team-based approach 9
• The European Heart Journal advises first follow-up within 10 days of discharge for optimal outcomes, including patient-centered discharge instructions with a clear transitional care plan 9
• For patients with atrial fibrillation and HF, the European Heart Journal considers amiodarone to convert to sinus rhythm and improve cardioversion success, with rate control as an acceptable alternative if rhythm control fails 9

Heart Failure Management Guideline

Initial Assessment and Therapy

• Administer loop diuretics immediately if pulmonary congestion or peripheral edema is present to rapidly improve dyspnea and exercise tolerance, as recommended by the European Society of Cardiology 10, 11
• Monitor continuously for at least 24 hours: heart rate, rhythm, blood pressure, and oxygen saturation, according to the American College of Cardiology 12
• Obtain 2D echocardiography with Doppler to assess left ventricular ejection fraction (LVEF), chamber size, wall thickness, and valve function, as suggested by the American College of Cardiology 12
• Perform 12-lead ECG and chest radiograph (PA and lateral) to evaluate cardiac structure and function, as recommended by the American College of Cardiology 12
• Laboratory evaluation should include complete blood count, urinalysis, electrolytes, BUN, creatinine, fasting glucose, lipid profile, liver function tests, and TSH to assess overall patient health, according to the American College of Cardiology 12

Core Pharmacological Therapy

• Start ACE inhibitors at low doses and uptitrate to target doses proven effective in clinical trials, as recommended by the European Society of Cardiology 10
• Sacubitril/valsartan (ARNI) is superior to ACE inhibitors and should replace enalapril in ambulatory HFrEF patients who remain symptomatic despite optimal therapy, according to the European Society of Cardiology 11
• Initiate beta-blockers even in the absence of fluid retention, or combine with diuretics if fluid retention is present, as suggested by the European Society of Cardiology 10
• Monitor renal function and electrolytes before initiation, 1-2 weeks after each dose increment, and at 3-6 month intervals when using ACE inhibitors or ARNI, as recommended by the European Society of Cardiology 10

Staging-Based Approach

• Focus on risk factor modification, including treating hypertension and hyperlipidemia aggressively, and consider ACE inhibitors or ARBs in appropriate high-risk patients, as recommended by the American College of Cardiology and the European Society of Cardiology 11, 12
• ACE inhibitors are mandatory for asymptomatic LV systolic dysfunction with history of MI to prevent or delay HF onset and prolong life, according to the European Society of Cardiology 11
• Consider ICD if LVEF ≤30% of ischemic origin at least 40 days post-MI, or if non-ischemic dilated cardiomyopathy with LVEF ≤30% on optimal medical therapy, as suggested by the European Society of Cardiology 11

Follow-Up Care

• First follow-up within 7-10 days of discharge for optimal outcomes, and telephone follow-up within 3 days, as recommended by the American College of Cardiology 12

Heart Failure Management with Guideline-Directed Therapy

Initial Approach and Staging-Based Assessment

• The American College of Cardiology/American Heart Association (ACC/AHA) recommends classifying patients according to ACC/AHA staging to guide treatment intensity, with Stage A (at risk, no structural disease) requiring aggressive treatment of hypertension and hyperlipidemia, and consideration of ACE inhibitors or ARBs in high-risk patients 13
• For patients with Stage B (structural disease, no symptoms), ACE inhibitors or ARBs are mandatory, particularly in those with prior MI and asymptomatic LV systolic dysfunction, with the addition of beta-blockers 13

Core Pharmacological Therapy for HFrEF

• The European Journal of Heart Failure suggests using forced-titration strategies from landmark trials to reach target doses proven effective in clinical trials, with documentation of intolerance if subtarget doses are necessary 14
• A patient receiving target doses of carvedilol, sacubitril/valsartan, and spironolactone represents true guideline-directed therapy, according to the European Journal of Heart Failure 14
• Attempting to reach target doses proven effective in clinical trials is crucial, as stated by the European Journal of Heart Failure 14